SON Stock Recent News

HARTSVILLE, S.C., March 10, 2025 (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco” or the “Company”) (NYSE: SON), a global leader in high-value sustainable paper and metal packaging, today announced it is implementing a $70 per ton price increase for all grades of uncoated recycled paperboard (URB) in the United States and Canada, effective with shipments beginning April 10, 2025.

Sonoco Products' shares have underperformed, down 19% over the past year, and are currently near a 52-week low. Sonoco's Q4 results were impacted by the Eviosys acquisition, causing messy financials and increased debt, but future EPS contributions should build throughout 2025. Management turnover and asset sales add uncertainty, with cash flow guidance disappointing despite expected EPS growth.

FCCO, URBN, BOH, MATX and SON have been added to the Zacks Rank #1 (Strong Buy) List on March 7, 2025.

SON, BOH and HWC made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 7, 2025.

Value investing is essentially about selecting cheap but fundamentally sound stocks. ENS, SON, VRNT and GM boast low P/CF ratios.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sonoco (SON) have what it takes?

Investors looking for stocks in the Containers - Paper and Packaging sector might want to consider either Sonoco (SON) or Packaging Corp. (PKG). But which of these two stocks presents investors with the better value opportunity right now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

HARTSVILLE, S.C., March 03, 2025 (GLOBE NEWSWIRE) -- Sonoco Products Company (NYSE: SON), a global leader in high-value sustainable packaging, announced that Andrea White, has been named Chief Human Resources Officer and has been elected a corporate officer by the Company's Board of Directors.

Poster presented at the 2025 AACR:IO Conference Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (F H AB ® )  provides enhanced targeting to the tumor microenvironment (TME) and prolonged retention in the tumor PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the presentation of a compilation of data at the 2025 American Association for Cancer Research (AACR) IO Conference.